CVS Health Corporation $CVS Shares Sold by Adams Diversified Equity Fund Inc.

Adams Diversified Equity Fund Inc. lessened its position in shares of CVS Health Corporation (NYSE:CVS) by 42.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 200,700 shares of the pharmacy operator’s stock after selling 150,600 shares during the quarter. Adams Diversified Equity Fund Inc.’s holdings in CVS Health were worth $14,414,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Kingsview Wealth Management LLC grew its position in shares of CVS Health by 316.2% in the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after purchasing an additional 79,340 shares during the period. Intech Investment Management LLC raised its position in shares of CVS Health by 50.3% during the 3rd quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock worth $6,526,000 after purchasing an additional 28,953 shares during the last quarter. Hamlin Capital Management LLC purchased a new position in CVS Health in the 4th quarter valued at about $160,844,000. Cresset Asset Management LLC lifted its stake in CVS Health by 56.8% in the 3rd quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock valued at $2,675,000 after buying an additional 12,849 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC acquired a new stake in CVS Health in the 3rd quarter worth about $11,308,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. UBS Group increased their target price on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a report on Monday, June 8th. TD Cowen lifted their price target on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. HSBC increased their price objective on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday, May 5th. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. Finally, Royal Bank Of Canada lifted their target price on shares of CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $101.28.

CVS Health Stock Down 0.3%

NYSE CVS opened at $104.38 on Friday. The business’s fifty day simple moving average is $91.81 and its 200-day simple moving average is $82.39. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The firm has a market cap of $133.18 billion, a PE ratio of 45.98, a P/E/G ratio of 1.02 and a beta of 0.62. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $106.15.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the firm posted $2.25 earnings per share. CVS Health’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts anticipate that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last 90 days. Insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.